Recent secondary market transactions have marked Neuralink at approximately $42–60 billion as of October 2026, reflecting a sharp increase from the $9.7 billion post-money valuation of its June 2025 Series E round. Trader sentiment for near-term valuation thresholds is supported by expanding clinical data, including over 50,000 hours of implant use across participants and a new foundation model achieving cursor control rates exceeding 11 bits per second, alongside ongoing FDA interactions and animal studies. With the October 31 resolution date approaching, limited additional primary funding or major regulatory milestones are expected in the immediate window, leaving secondary trading activity and any incremental trial updates as the key variables that could influence market-implied odds.